Application of ramazolam besylate in nerve block assisted sedation and painless diagnosis and treatment techniques

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200066534

Enrollment

Unknown

Registered

2022-12-08

Start date

2022-01-03

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

The remazolam group:Remazolam besylate is used in painless treatment

Rematazolam besylate combined with propofol group 1:Using remazolam besylate 3mg combined with propofol in painless treatment

Rematazolam besylate combined with propofol group 2:Using remazolam besylate 5mg combined with propofol in painless treatment

The propofol group:Propofol will be administered for sedation in painless treatment

Nerve block: the remazolam group:Administer auxiliary sedation to patients undergoing nerve block surgery use remazolam besylate

Nerve block: propofol group:Administer auxiliary sedation to patients undergoing nerve block surgery use propofol

Nerve block: rematazolam besylate combined with propofol group 2:Administer auxiliary sedation to patients undergoing nerve block surgery use remazolam besylate 5mg combined with propofol

Nerve block: rematazolam besylate combined with propofol group 1:Administer auxiliary sedation to patients undergoing nerve block surgery use remazolam besylate 3mg combined with propofol

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years; 2. ASA?~?; 3. Patients receiving elective nerve block assisted sedation or painless diagnosis and treatment; 4. BMI 18.5-25kg/m^2; 5. Check for 20-60 minutes.

Exclusion criteria

Exclusion criteria: 1. The patient explicitly refuses to participate in the study; 2. Patients with a history of serious heart, brain, lung, liver, kidney and metabolic diseases; 3. Patients with a history of recovery from abnormal surgical anesthesia; 4. Electrocardiogram: heart rate =180mmHg and/or 110mmHg in hypertensive patients, or <=90/60mmHg in hypotensive patients; 7. Patients with neuromuscular system diseases, mental system diseases and cognitive dysfunction; 8. Suspected abuse of narcotic analgesics or sedatives; 9. Those who predict that difficult airway may occur or have occurred before; 10. Pregnant or lactating patients.

Design outcomes

Primary

Measure	Time frame
Hypoxemia;	—

Secondary

Measure	Time frame
Changes in vital signs;Modified observer's assessment of alert /sedation rating;Onset time;Wake-up time;The patient wakes up until the time they leave the operating room;Adverse reactions within 24 hours after surgery;Satisfaction rating;Body movement grading;	—

Countries

China

Contacts

Public ContactJin Hua

The First People's Hospital of Yunnan Province

jinhuakm@163.com+86 13888668869

Outcome results